Glucose-peg conjugates for reducing glucose transport into a cell

Abstract

There is provided a glucose-PEG conjugate comprising a PEG moiety conjugated to a linear glucose moiety at the C1 position of the glucose moiety. The glucose-PEG conjugate may be used to reduce glucose transport into a cell and may be used to treat a proliferative disorder.

1 . A glucose-PEG conjugate comprising 
       
         
           
           
               
               
           
         
         wherein each n is independently from 2 to 500. 
       
     
     
         2 . The glucose-PEG conjugate of  claim 1  further comprising a detectable label. 
     
     
         3 . The glucose-PEG conjugate of  claim 2  wherein the detectable label is a PET label, an SPECT label, an MRI label, a quantum dot label, a coloured label, a fluorescent label, a radiolabel or a label that may be detected by an antibody or antibody fragment. 
     
     
         4 . The glucose-PEG conjugate of  claim 2  comprising 
       
         
           
           
               
               
           
         
       
     
     
         5 . A method of reducing glucose transport into a cell comprising contacting the cell with a glucose-PEG conjugate, the glucose-PEG conjugate comprising a PEG moiety conjugated to a linear glucose moiety at the C1 position of the glucose moiety. 
     
     
         6 . The method of  claim 5  wherein the PEG moiety comprises linear, branched, dendritic, hyperbranched, star or comb PEG. 
     
     
         7 . The method of  claim 5  wherein the PEG moiety is conjugated to the C1 position of the glucose moiety via an amine linkage. 
     
     
         8 . The method of  claim 5  wherein the PEG moiety is terminated at one or both ends with an end group. 
     
     
         9 . The method of  claim 5  wherein the glucose-PEG conjugate further comprises a linker moiety connecting the PEG moiety to the glucose moiety. 
     
     
         10 . The method of  claim 5  wherein the glucose-PEG conjugate is the glucose-PEG conjugate of  claim 1 . 
     
     
         11 . The method of  claim 5  wherein the glucose-PEG conjugate further comprises a detectable label. 
     
     
         12 . The method of  claim 11  wherein the detectable label is a PET label, an SPECT label, an MRI label, a quantum dot label, a coloured label, a fluorescent label, a radiolabel or a label that may be detected by an antibody or antibody fragment. 
     
     
         13 . The method of  claim 10  wherein the glucose-PEG conjugate comprises 
       
         
           
           
               
               
           
         
       
     
     
         14 . The method of  claim 5  wherein the cell is a hyper-proliferative cell. 
     
     
         15 . A method of imaging a hyper-proliferative cell comprising contacting a hyper-proliferative cell with a glucose-PEG conjugate of  claim 2 ; and detecting the detectable label. 
     
     
         16 . The method of  claim 15  wherein detecting involves fluorescence microscopy, positron emission tomography imaging, single photon emission computed tomography imaging or magnetic resonance imaging. 
     
     
         17 - 18 . (canceled) 
     
     
         19 . The method of  claim 15  wherein the cell is associated with a proliferative disorder. 
     
     
         20 . The method of  claim 19  wherein contacting comprises administering an effective amount of the glucose-PEG conjugate at the site of a hyper-proliferating cell in a subject. 
     
     
         21 . The method of any one of  claims 14  to  20  further comprising contacting the cell with a chemotherapeutic agent. 
     
     
         22 . A pharmaceutical composition comprising a glucose-PEG conjugate of  claim 1 . 
     
     
         23 - 36 . (canceled) 
     
     
         37 . The method of  claim 5  wherein the cell is associated with a proliferative disorder. 
     
     
         38 . The method of  claim 37  wherein contacting comprises administering an effective amount of the glucose-PEG conjugate at the site of a hyper-proliferating cell in a subject.